tbuckley/cabot-search huggingface dataset:
OP0277-PARE Patient Research Partners Involved in A Project To Enhance Disease-Associated Communications Skills of Rheumatoid Patients
Authors: J. Clausen, P. Böhm, E. Farin-Glattacker, A. Thyrolf
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with chronic diseases often have to conduct conversations that are associated with their disease, either to pursue their own interests or to justify their personal restrictions. The ability to communicate with confidence may be considered a precondition for social participation. Because social participation is one of the key concerns of the Deutsche Rheuma-Liga (DRL), the DRL has funded a research project for enhancing the communication skills of people suffering from rheumatic diseases. The project involved key participation by DRL9s- patient research partners (PRPs), who related their own communication limitations as well as providing input to the design of a novel programme of communication skill training. The experience gained and the various contributions of the PRPs will be presented. <h3>Objectives</h3> The aim of the project was the inclusion of PRPs in a scientific study that identifies, and subsequently seeks to enhance, those areas of life in which patients with rheumatic diseases experience the most problems during conversations. <h3>Methods</h3> PRPs were trained during a two-day interactive training course based on EULAR recommendations. Obstacles during disease-associated conversations were identified via an online questionnaire. The results of this analysis fed into a new programme of communication skills training. <h3>Results</h3> The PRPs felt they were being treated on equal terms and that they were being taken seriously by the researchers. Their proposals were implemented by the researchers, if possible, and they took part in all substantial meetings of the research project. The PRPs were actively involved in: i) the preparation of the information leaflet describing the online questionnaire; ii) the preparation of the online questionnaire itself; iii) designing the course of the interviews; iv) disseminating information about the study. Thereafter, the PRPs participated in: v) designing the various modules of the communication skill training; vi) the training handbook9s preparation; vii) the information leaflets promoting and describing the skill training. Moreover, the PRPs will operate the first test runs of the skill training. Altogether, the participation in the research project was acclaimed as interesting and enriching by the PRPs. <h3>Conclusions</h3> The implementation of the patient9s perspective through inclusion of the PRPs was successful and gave important impetus. The usefulness and effectivity of the new training programme will be evaluated in a future randomised, controlled trial. <h3>Acknowledgement</h3> The authors wish to thank the following patient research partners for participating in the study: R. Choijnacki, U. Garske and I. Kimmerle. We also thank the following investigators: J. Lamprecht, W. Mau, M. Schlöffel and A. Schöpf. <h3>Disclosure of Interest</h3> None declared
Bortezomib-Resistance Is Characterized By Upregulation of E3 Ligase Pirh2 Which Protects Bortezomib Induced Apoptosis in Multiple Myeloma Cells
Authors: Li Yang, Jingsong He, Yi Li, Xing Guo, Jing Chen, Qingxiao Chen, Xuanru Lin, Donghua He, Yang Yang, Enfan Zhang, Xiaoyan Han, Wenjun Wu, Yi Zhao, Gaofeng Zheng, He Huang, Zhen Cai
Journal: Blood (2014)
Chronic Myeloid Leukemia (CML): BCR-ABL Transcript Levels Halving Time and Relative Reduction Ratio at Months 3 As New Predictors of Outcome. an Argentine Pilot Study
Authors: Isabel Amanda Giere, María Jose Mela Osorio, Federico Andrés Klosowski, Mariana Debus, Ana Inés Varela, Elena Beatriz Moiraghi, Miguel A Pavlovsky, Isolda Fernandez, Dante Intile, Carolina Pavlovsky
Journal: Blood (2015)
Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis
Authors: Jamie Robertson, Duncan Porter, Naveed Sattar, Chris J Packard, Muriel Caslake, Iain McInnes, David McCarey
Journal: Annals of the Rheumatic Diseases (2017)

Objectives Patients with rheumatoid arthritis (RA) have reduced serum low-density lipoprotein cholesterol (LDL-c), which increases following therapeutic IL-6 blockade. We aimed to define the metabolic pathways underlying these lipid changes. Methods In the KALIBRA study, lipoprotein kinetic studies were performed on 11 patients with severe active RA at baseline and following three intravenous infusions of the IL-6R blocker tocilizumab. The primary outcome measure was the fractional catabolic rate (FCR) of LDL. Results Serum total cholesterol (4.8 vs 5.7 mmol/L, p=0.003), LDL-c (2.9 vs 3.4 mmol/L, p=0.014) and high-density lipoprotein cholesterol (1.23 vs 1.52 mmol/L, p=0.006) increased following tocilizumab therapy. The LDL FCR fell from a state of hypercatabolism to a value approximating that of the normal population (0.53 vs 0.27 pools/day, p=0.006). Changes in FCR correlated tightly with changes in serum LDL-c and C-reactive protein but not Clinical Disease Activity Index. Conclusions Patients with RA have low serum LDL-c due to hypercatabolism of LDL particles. IL-6 blockade normalises this catabolism in a manner associating with the acute phase response (and thus hepatic IL-6 signalling) but not with RA disease activity as measured clinically. We demonstrate that IL-6 is one of the key drivers of inflammation-driven dyslipidaemia.
Genetics of Infectious and Inflammatory Diseases: Overlapping Discoveries from Association and Exome-Sequencing Studies
Authors: David Langlais, Nassima Fodil, Philippe Gros
Journal: Annual Review of Immunology (2016)

Genome technologies have defined a complex genetic architecture in major infectious, inflammatory, and autoimmune disorders. High density marker arrays and Immunochips have powered genome-wide association studies (GWAS) that have mapped nearly 450 genetic risk loci in 22 major inflammatory diseases, including a core of common genes that play a central role in pathological inflammation. Whole-exome and whole-genome sequencing have identified more than 265 genes in which mutations cause primary immunodeficiencies and rare forms of severe inflammatory bowel disease. Combined analysis of inflammatory disease GWAS and primary immunodeficiencies point to shared proteins and pathways that are required for immune cell development and protection against infections and are also associated with pathological inflammation. Finally, sequencing of chromatin immunoprecipitates containing specific transcription factors, with parallel RNA sequencing, has charted epigenetic regulation of gene expression by proinflammatory transcription factors in immune cells, providing complementary information to characterize morbid genes at infectious and inflammatory disease loci.
Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.
Authors: Madeleine Duvic, Youn H. Kim, Timothy M. Kuzel, Theresa R. Pacheco, Francine M. Foss, Sareeta Parker, Stanley R. Frankel, Cong Chen, Justin L. Ricker, Jean Marie Arduino, Sophia Randolph, Victoria M. Richon, Elise A. Olsen
Journal: Blood (2006)
First-Line Treatment with Rituximab Improves Survival of Patients with Post-Transplant Lymphoproliferative Disease (PTLD).
Authors: E. Gonzalez-Barca, E. Domingo-Domenech, J. Gomez-Codina, F. Capote, E. Flores, J. Briones, A. Salar, C. Panizo, C. Montalban, J. M. Ribera, D. Caballero, A. Muñoz, L. Gallur, M.A. Canales, P. Fernandez, M. Encuentra, A. Fernandez de Sevilla
Journal: Blood (2004)
Short Chemotherapy-Phased Imatinib (IM) Pulses Improve Long-Term Outcome of Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL).
Authors: Renato Bassan, Giuseppe Rossi, Enrico Maria Pogliani, Eros Di Bona, Emanuele Angelucci, Irene Cavattoni, Agostino Cortelezzi, Giacomo Gianfaldoni, Alessandro Levis, Fabio Ciceri, Daniele Mattei, Erika Borlenghi, Elisabetta Terruzzi, Carlo Borghero, Claudio Romani, Orietta Spinelli, Manuela Tosi, Elena Oldani, Tamara Intermesoli, Alessandro Rambaldi
Journal: Blood (2009)
Rituximab-Based Treatments Followed By Adoptive Cellular Therapies For EBV-Associated Post-Transplant Lymphoproliferative Disease In Recipients Of Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Xinmiao Jiang, Lanping Xu, Yu Zhang, Fen Huang, Daihong Liu, Jing Sun, Chaoyang Song, Xinquan Liang, Zhiping Fang, Hongsheng Zhou, Min Dai, Can Liu, Qianli Jiang, Na Xu, Li Xuan, Meiqing Wu, Xiaojun Huang, Qifa Liu
Journal: Blood (2013)
Frontline High Dose Chemotherapy Supported by Autologous PBSCT Might Improve Survival In Elderly Patients (≥60 Years) with High Risk Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Vadim Ivanov, Diane Coso, Jerome Rey, Therese Aurran-Schleinitz, Anne-Marie Stoppa, Jean-Marc Schiano de Colella, Didier Blaise, Reda Bouabdallah
Journal: Blood (2010)
PTH-057 Pregnancy and IBD; Do We Provide Enough Patient Education? A British Study of 1324 Women
Authors: I Carbery, C Selinger
Journal: Gut (2016)

<h3>Introduction</h3> Inflammatory Bowel Disease (IBD) is a complex condition affecting many young women of child bearing age. Knowledge of IBD and pregnancy related issues is key to enable patients to make informed decisions. This study aims to ascertain knowledge and factors influencing knowledge using the validated Crohn’s and Colitis Pregnancy Knowledge Score (CCPKnow) in British women with IBD. <h3>Methods</h3> Approximately 4300 female members of Crohn’s and Colitis UK, aged between 18–45 years were sent an online questionnaire via email. Data collection included patient demographics, education, employment, marital status, and disease characteristics. Disease related pregnancy knowledge was recorded using CCPKnow. <h3>Results</h3> A total of 1324 women completed the survey (response rate 31%) with a mean age of 33 years. Of these 776 (59%) suffered from Crohn’s disease (CD), 496 (38%) from ulcerative colitis (UC) and 52 (4%) from IBD-U. CCPknow scores were poor (0–7) in 50.8%, adequate (8–10) in 23.6%, good (11–13) in 17.7% and very good (≥14) in 7.8%. Higher CCPKnow scores were associated with higher educational achievement (masters/PHD 8.67 vs secondary school 5.99, p &lt; 0.001), working (full time employment 7.18 vs unemployed 6.12, p = 0.03) and marital status (long-term relationship 7.60 vs single 6.26, p &lt; 0.001). Patients with CD (7.51 vs UC 6.97; p = 0.026) and those with more severe disease had better knowledge (hospital admission 7.59 vs none 6.66, p &lt; 0.001; surgery 7.71vs none 7.12, p = 0.018; current biological therapy 8.30 vs none 7.05, p &lt; 0.001). Speaking to health care professionals was also associated with better CCPKnow scores (Gastroenterologist 9.18 vs no 6.25, p &lt; 0.001), (GP 8.44 vs no 6.98, p &lt; 0.001), (Specialist IBD nurse 9.27 vs 6.83, p &lt; 0.001). Ethnicity and same sex relationships had no influence on CCPKnow scores. <h3>Conclusion</h3> In this large study of British women with IBD knowledge was poor in over half of patients. Patients with CD and higher disease burden had better knowledge but education, employment and being in a relationship also had a positive influence on CCPKnow score. Speaking with health care professionals about pregnancy was identified as a modifiable factor associated with better knowledge. This study illustrates the importance of disease related education for female patients with IBD and highlights that health professionals, of any vocation, should seek opportunities to educate patients about pregnancy and IBD early in their disease course. <h3>Disclosure of Interest</h3> I. Carbery: None Declared, C. Selinger Grant/research support from: Abbvie, Warner Chilcott, Consultant for: Abbvie, Warner Chilcott, Dr Falk, Takeda, Speaker bureau with: Abbvie, Warner Chilcott, MSD, Takeda
Haploinsufficiency of TNFAIP3 ( A20 ) by germline mutation is involved in autoimmune lymphoproliferative syndrome
Authors: Masatoshi Takagi, Shohei Ogata, Hiroo Ueno, Kenichi Yoshida, Tzuwen Yeh, Akihiro Hoshino, Jinhua Piao, Motoy Yamashita, Mai Nanya, Tsubasa Okano, Michiko Kajiwara, Hirokazu Kanegane, Hideki Muramatsu, Yusuke Okuno, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Yuki Bando, Motohiro Kato, Yasuhide Hayashi, Satoru Miyano, Kohsuke Imai, Seishi Ogawa, Seiji Kojima, Tomohiro Morio
Journal: Journal of Allergy and Clinical Immunology (2016)
SAT0525 The Use of Analgesic and Other Pain Relief Drugs To Manage Chronic Low Back Pain – Results from A National Survey: Table 1.
Authors: N. Gouveia, A. Rodrigues, S. Ramiro, M. Eusébio, P.M. Machado, H. Canhão, J.C. Branco
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Managing chronic pain is challenging due to the long-term safety profile of most drugs. The treatment of chronic Low Back Pain (CLBP) represents a significant medical and financial burden and aims at relieving pain, improving functional ability, and preventing recurrence and chronicity. It is therefore important to gain insight into how CLBP is managed in the population. <h3>Objectives</h3> To characterize the intake profile of analgesic and other pain relief drugs in the Portuguese adult population with CLBP, taking the World Health Organization (WHO) analgesic ladder and pain intensity into account. To assess the relationship between having CLBP and the intake of analgesic and other pain relief drugs. <h3>Methods</h3> EpiReumaPt was a cross-sectional Portuguese population-based study (10,661 subjects). Self-reported active CLBP (ACLBP) was considered: LBP on the day of enrollment and for ≥90 days. Prevalence and profile of analgesic intake was characterized among those self-reporting ACLBP, taking into account the intensity of pain and the WHO analgesic ladder. To understand whether the presence of ACLBP was a factor associated with drug intake, multivariable logistic regressions were conducted for each of the analgesic/pain relief therapeutic groups (in separate models), adjusted for confounders. <h3>Results</h3> Among 1,487 subjects with ACLBP, 18.7% were using analgesic/pain relief drugs. Estimated prevalences were: anxiolytics, 14.1%; NSAIDs, 12.3%; antidepressants, 10.1%; analgesic antipyretic, 6.6%; anticonvulsants, 3,4%; central muscle relaxants, 2.6%; opioids, 1.6%. Most subjects with severe pain were in the 1st step of the WHO analgesic ladder: NSAIDs plus anxiolytics, sedatives &amp; hypnotics (4.6%); NSAIDs plus antidepressants (3.2%); NSAIDs plus central muscle relaxants (2.5%). The presence of ACLBP was significantly associated with the intake of all therapeutic groups (table): <h3>Conclusions</h3> ACLPB was associated with the intake of drugs belonging to all analgesic drug classes. Nevertheless, this drug intake was very low, even for those with severe pain. The WHO analgesic ladder was carefully followed with an extremely conservative use of analgesic opioids even for those with severe pain. There is clearly an unmet need in what concerns pain management in patients with ACLBP, particularly taking into account the well-know burden of LBP. <h3>Disclosure of Interest</h3> None declared
Improved Post-Thaw Viability and In Vitro Functionality of Peripheral Blood Hematopoietic Progenitor Cells after Cryopreservation with a Theoretically Optimized Freezing Curve.
Authors: Marloes R. Tijssen, Henri Woelders, Ada de Vries-van Rossen, C. Ellen Van der Schoot, Carlijn Voermans, Johan W.M. Lagerberg
Journal: Blood (2007)
Phase I Clinical Trial of Glivec in Combination with Tetra-Arsenic Tetra-Sulfide in the Treatment of CML Patients in Advanced Phase.
Authors: Jun-Min Li, Ai-Hua Wang, Hui-Ping Sun, Yang Shen, Rui-Hua Zhao, Bai-Wei Gu, Bing Chen, Wen Xing, Zhi-Xiang Shen, Zhen-Yi Wang, Sai-Juan Chen, Zhu Chen
Journal: Blood (2004)
Association of a Blood Glucose Test Strip Quantity-Limit Policy With Patient Outcomes
Authors: Tara Gomes, Diana Martins, Mina Tadrous, J. Michael Paterson, Baiju R. Shah, Jack V. Tu, David N. Juurlink, Anna Chu, Muhammad M. Mamdani
Journal: JAMA Internal Medicine (2016)

<h3>Importance</h3> Given their high costs, payers have considered implementing quantity limits for reimbursement of blood glucose test strips. The effect of these limits on patient outcomes is unknown. <h3>Objective</h3> To determine whether the introduction of quantity limits for blood glucose test strips in August 2013 was associated with changes in clinical outcomes. <h3>Design, Setting, and Participants</h3> Cross-sectional time series analysis from April 2008 to March 2015 of residents of Ontario, Canada, aged 19 years and older with diabetes who were eligible for public drug coverage. In a sensitivity analysis, we studied high-volume users of test strips, who were most likely to be affected by the quantity limits. <h3>Exposures</h3> Eligible patients were stratified into 4 mutually exclusive groups based on diabetes therapy: insulin, hypoglycemia-inducing oral diabetes agents, nonhypoglycemia-inducing oral diabetes agents, and no drug therapy. <h3>Main Outcomes and Measures</h3> The primary outcome was emergency department visits for hypoglycemia or hyperglycemia, and the secondary outcome was mean hemoglobin A1c (HbA1c) levels. Outcomes were measured for all patients in each quarter, stratified by age group (&lt;65 vs ≥65 years) and diabetes therapy. <h3>Results</h3> By the end of the study period, 834 309 people met inclusion criteria. Among those younger than 65 years, the rate of hypoglycemia and hyperglycemia declined over the study period (from 4.9 to 3.0 visits per 1000 Ontario drug benefit [ODB]-eligible patients and from 4.2 to 3.6 visits per 1000 ODB-eligible patients, respectively) and was not significantly associated with the introduction of quantity limits (<i>P</i> = .67 and<i>P</i> = .37, respectively). Similarly, among those aged 65 years and older, rates of hypoglycemia and hyperglycemia declined over the study period (from 2.9 to 1.3 visits per 1000 eligible patients and from 0.8 to 0.5 visits per 1000 eligible patients, respectively) and was not significantly associated with the introduction of quantity limits (<i>P</i> = .12 and<i>P</i> = .24, respectively). Results were consistent for the secondary outcome of mean HbA1c levels and in the sensitivity analysis of high-volume test strip users. <h3>Conclusions and Relevance</h3> The imposition of quantity limits for blood glucose test strips was not associated with worsening short-term outcomes, suggesting that these policies can reduce costs associated with test strips without causing patient harm.
Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges
Authors: Giovanni Musso, Maurizio Cassader, Elena Paschetta, Roberto Gambino
Journal: Hepatology (2016)

Musso, Giovanni M.D; Cassader, Maurizio Ph.D; Paschetta, Elena M.D; Gambino, Roberto Ph.D Author Information
A Phase II Trial of Busulfan, Melphalan, and Fludarabine followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants from HLA-Identical, or HLA-Non Identical Related or Unrelated Donors for the Treatment of Advanced Hematopoietic Malignancies.
Authors: Farid Boulad, Ann Jakubowski, Hugo Castro-Malaspina, Katharine C. Hsu, Nancy A. Kernan, Esperanza B. Papadopoulos, Miguel A. Perales, Susan E. Prockop, Trudy N. Small, Marcel R.M. van den Brink, James W. Young, Michelle Ro, Nancy Collins, Richard J. O’Reilly
Journal: Blood (2004)
AB0277 Comparison between Intima-Media Thickness and Coronary Artery Tomography in Subclinical Atherosclerosis Detection in Rheumatoid Arthritis:
Authors: L. Riancho-Zarrabeitia, A. Corrales, J.A. Parra, M. Santos-Gόmez, V. Portilla, P. Dessein, R. Blanco, M.A. González-Gay
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Intima media thickness (IMT) and coronary artery calcification (CAC) quantification using multidetector computed tomography (MDCT) scanner are useful in detecting subclinical atherosclerosis and are good surrogate markers of cardiovascular morbidity and mortality in general population and in rheumatoid arthritis (RA) A good correlation between these methods has been reported in RA, being CAC a slightly more sensitive technique (1) <h3>Objectives</h3> Our aim is to determine the value of IMT that better predicts the presence of coronary atherosclerosis, using CAC as reference and assuming CAC value of 100 as the cut-off point indicating high cardiovascular risk. <h3>Methods</h3> We evaluated 127 RA patients without previous cardiovascular events. Carotid ultrasonography was performed by a MyLab 70 scanner (Esaote; Genoa, Italy), equipped with 7–12 MHz linear transducer and the <i>automated software guided technique radiofrequency</i> – <i>Quality Intima Media Thickness</i> in <i>real</i>-<i>time</i> (<i>QIMT</i>, <i>Esaote</i>, <i>Maastricht</i>, <i>Holland</i>). According to data from non-rheumatic patients and also from RA patients, an IMT≥0.90 mm is a good predictor of high cardiovascular risk. To determine CAC score, a CT Imaging of coronary arteries using a 32-slice MDCT scanner (Lightspeed, Pro 32, GE Healthcare, USA) was performed. <h3>Results</h3> Patients with IMT below 0.90 mm had CAC values of 88±210 whereas patients with IMT≥0.90 mm had mean CAC values of 190± 272 (p=0.066). We found a positive correlation between IMT and CAC (correlation coefficient 0,303; p=0.001). The IMT cut-off value ≥0.90 mm had a sensitivity of 32% for detecting CAC ≥100. ROC curve analysis showed and area under the curve of 0.664. The IMT cut-off value of 0.80 mm had a sensitivity of 40% and a specificity of 71.3%. Lowering the IMT cut-off point to 0.70, we reached a sensitivity of 76% and a specificity of 51.5% for CAC ≥100 detection. The positive predictive value for the IMT cut-off point of 0.70 mm was 76% in our population, being the negative predictive value 49.5% <h3>Conclusions</h3> IMT values ≥0.70 mm predict coronary artery calcification score above 100 with a sensitivity of 76%. According to that, the IMT value considered as predictor of high cardiovascular risk would be 0.70 mm instead of 0.90 mm. <h3>References</h3> Corrales A et al. "Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than coronary artery calcification score to detect subclinical atherosclerosis in patients with rheumatoid arthritis" Ann Rheum Dis. 2013,72 1764–1770. <h3>Disclosure of Interest</h3> None declared
Spleen Stiffness Measurement By Transient Elastography As a Predictor of Bone Marrow Fibrosis in Primary Myelofibrosis Patients
Authors: Alessandra Iurlo, Daniele Cattaneo, Mariangela Giunta, Umberto Gianelli, Giovanni Casazza, Mirella Fraquelli, Nicola Orofino, Cristina Bucelli, Paola Bianchi, Claudia Augello, Silvano Bosari, Massimo Colombo, Agostino Cortelezzi
Journal: Blood (2014)
Unrelated Cord Blood Transplantation for Severe Acquired Aplastic Anemia Using a Reduced-Intensity Conditioning: High Graft Rejection but Good Survival
Authors: Huilan Liu, Liangquan Geng, Xingbing Wang, Kaiyang Ding, Baolin Tang, Juan Tong, Wen Yao, Zuyi Wang, Zimin Sun
Journal: Blood (2010)